| TI: Adherence: a necessity for successful HIV combination therapy
AU: Chesney, M. A.; Ickovics, J.; Hecht, F. M.; Sikipa, G.; Rabkin, J. | Pág. S271-S278 |
| TI: Advances in understanding the evolution of HIV
AU: Crandall, K. A.; Vasco, D. A.; Posada, D.; Imamichi, H. | Pág. S39-S48 |
| TI: Anti-HIV cellular immunity: recent advances towards vaccine design
AU: Goulder, P. J. R.; Rowland-Jones, S. L.; McMichael, A. J.; Walker, B. D. | Pág. S121-S136 |
| TI: Behavioral and social science: overview
AU: Jarlais, D. D.; Caraeel, M. | Pág. S235-S238 |
| TI: Clinical treatment: overview
AU: Yarchoan, R.; Vella, S. | Pág. S175-S176 |
| TI: Changes in HIV and AIDS epidemiology from new generation antiretroviral therapy
AU: Weidle, P. J.; Holmberg, S. D.; DeCock, K. M. | Pág. S61-S68 |
| TI: Drug injecting, rapid HIV spread, and the 'risk environment': implications for assessment and response
AU: Rhodes, T.; Stimson, G. V.; Crofts, N.; Ball, A.; Dehne, K.; Khodakevich, L. | Pág. S259-S270 |
| TI: Epidemiology: overview
AU: Padian, N.; Buve, A. | Pág. S59-S60 |
| TI: HIV prevention among vulnerable populations: outreach in the developing world
AU: Tawil, O.; O'Reillv, K.; Coulibaly, I. M.; Tiemele, A.; Himmich, H.; Boushaba, A.; Pradeep, K.; Caraeel, M. | Pág. S239-S248 |
| TI: Human trials of HIV-1 vaccines
AU: Mulligan, M. J.; Weber, J. | Pág. S105-S112 |
| TI: Immune reconstitution in HIV infection
AU: Gea-Banacloche, J. C.; Lane, H. C. | Pág. S25-S38 |
| TI: Interruption of materno-fetal transmission
AU: Mofenson, L. M.; Fowler, M. G. | Pág. S205-S214 |
| TI: Interventions to reduce mother-to-child transmission of HIV infection: new developments and current controversies
AU: Gibb, D. M.; Tess, B. H. | Pág. S93-S102 |
| TI: Latency and reservoirs for HIV-1
AU: Siliciano, R. F. | Pág. S49-S58 |
| TI: Low fertility in women with HIV and the impact of the epidemic on orphanhood and early childhood mortality in sub-Saharan Africa
AU: Gregson, S.; Zaba, B.; Garnett, G. P. | Pág. S249-S258 |
| TI: Microbicides and barrier methods in HIV prevention
AU: Van Damme, L.; Rosenberg, Z. F. | Pág. S85-S92 |
| TI: Molecular interactions of HIV with host factors
AU: Strebel, K.; Bour, S. | Pág. S13-S24 |
| TI: Murine models for HIV disease
AU: Jamieson, B. D.; Zack, J. A. | Pág. S5-S12 |
| TI: New approaches to managing opportunistic infections
AU: Lundgren, J.; Masur, H. | Pág. S227-S234 |
| TI: New insights and approaches regarding B- and T-cell epitopes in HIV vaccine design
AU: Oscherwitz, J.; Gotch, F. M.; Cease, K. B.; Berzofsky, J. A. | Pág. S163-S174 |
| TI: Protease inhibitors: resistance, cross-resistance, fitness and the choice of initial and salvage therapies
AU: Erickson, J. W.; Gulnik, S. V.; Markowitz, M. | Pág. S189-S204 |
| TI: The neutralizing antibody response to HIV-I: viral evasion and escape from humoral immunity
AU: Parren, P. W. H. I.; Moore, J. P.; Burton, D. R.; Sattentau, Q. J. | Pág. S137-S162 |
| TI: The role of nonhuman primates in the development of an AIDS vaccine
AU: Nathanson, N.; Hirsch, V. M.; Mathieson, B. J. | Pág. S113-S120 |
| TI: The year in review: antiretroviral treatment
AU: Hirschel, B.; Opravil, M. | Pág. S177-S188 |
| TI: Towards a better understanding of the epidemiology of HIV-2
AU: Van der Loeff, M. F. S.; Aaby, P. | Pág. S69-S84 |
| TI: Treatment update for AIDS-related Kaposi's sarcoma
AU: Mihalcea, A. M.; Smith, D. L.; Monini, P.; Sgadari, C.; Ensoli, B.; Gill, P. S. | Pág. S215-S226 |
| TI: Vaccines and immunology: overview
AU: Stott, J.; Hahn, B. H. | Pág. S103-S104 |
| TI: Virology: overview
AU: Folks, T.; Harada, S. | Pág. S1-S4 |